The HCA Midwest Health clinical research program supports overall patient care by offering another therapeutic option through clinical trials. These clinical studies are available through the Kansas City Clinical Oncology Program (KCCOP), Sarah Cannon Research Institute, and various pharmaceutical and CRO partners.

AML 40: A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia. PI: Suman Kambhampati, MD
Facility: Research Medical Center

AML 43: Randomized (1:1), double-blind, multi-center, placebo controlled study evaluating intensive chemotherapy with or without glasdegib (pf-04449913) or azacitidine (aza) with or without glasdegib in patients with previously untreated acute myeloid leukemia. PI: Suman Kambhampati, MD
Facility: Research Medical Center

CLL 45: Previously Untreated Chronic Lymphocytic Leukemia (CLL): Debulking Regimens Prior to Initiating Venetoclax Combination Therapy in Frontline CLL Excluding 17p Deletion. PI: Dr Suman Kambhampati
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

CLL 48: A Phase 3, Study of Zanubrutinib (BGB-3111) vs Ibrutinib in Relapsed/Refractory CLL or SLL. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LYM 132: A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kä Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203). PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LYM 145: Phase II study of Tenalisib (RP6530), a novel PI3K ä/ã dual inhibitor in relapsed/refractory indolent Non-Hodgkin’s Lymphoma (iNHL). PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MDS 21: A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia. PI: Suman Kambhampati, MD
Facility: Research Medical Center

MDS 22: Phase 3, Study of Luspatercept versus Epoetin alfa for Anemia due to IPSS-R Very Low, Low or Intermediate Risk MDS in ESA Naïve Subjects who require Red Blood Cell Transfusions. PI: Suman Kambhampati, MD
Facility: Research Medical Center

MDS 24: A Phase III, Study of Rigosertib versus Physicians Choice of Treatment in MDS after Failure of a Hypomethylating Agent. PI: Suman Kambhampati, MD
Facility: Research Medical Center

MM 109: Study of Daratumumab + Lenalidomide vs. Lenalidomide Alone as Maintenance in newly diagnosed MM Who Are MRD + after Frontline Autologous Stem Cell Transplant. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 287: Phase I-II trial of H3B-6545, an antagonist of estrogen receptor alpha, in locally advanced/metastatic ER +, HER2 - breast cancer. PI:  Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 293:

A phase III randomized study to investigate the efficacy and safety of atezolizumab (anti-pd-l1 antibody) in combination with neoadjuvant anthracycline-based chemotherapy compared with placebo and chemotherapy in patients with primary invasive triple-negative breast cancer. PI: Stephanie Graff, MD


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 302: Phase 2 study of MCLA-128-based combinations in metastatic breast cancer (MBC): MCLA-128/trastuzumab/chemotherapy in HER2-positive MBC and MCLA-128/endocrine therapy in estrogen receptor positive and low HER2 expression MBC. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 303: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 304: A phase III, randomized, placebo-controlled, multicenter study of the efficacy and safety of atezolizumab plus chemotherapy in the treatment of early-relapsing locally recurrent inoperable or metastatic triple-negative breast cancer. PI: Dr Stephanie Graff
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 310:

Phase III, Study of Atezolizumab + Standard Adjuvant Anthracycline/Taxane-Based Chemo Versus Chemo Alone In Operable TNBC. PI: Stephanie Graff, MD


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 312:

Phase III trial of xentuzumab in combo w/everolimus and exemestane vs everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease. PI: Stephanie Graff, MD


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 317:

Phase 3, study of ds-8201a, an anti-her2-antibody drug conjugate, vs ado-trastuzumab emtansine (t-dm1) for her2 +, unresectable and/or mbc subjects previously treated with trastuzumab and taxane. PI: Stephanie Graff, MD


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 319: A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of atezolizumab or placebo in combination with neoadjuvant doxorubicin + cyclophosphamide followed by paclitaxel + trastuzumab + pertuzumab in early her2-positive breast cancer (impassion050). PI: Dr Stephanie Graff
Facility: Menorah Medical Center

BRE 322: Phase III, trial of ribociclib with endocrine therapy as an adjuvant treatment in HR +, HER2 -, early breast cancer (NATALEE). PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 328: Open, Randomized, Study of Lasofoxifene Relative to Fulvestrant in Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

Amaze – SentreHeart: Evaluate the safety and effectiveness of the Lariat Suture Delivery system to percutaneously isolate and ligate the LAA from the LA as an adjunct to a planned PVI catheter ablation in persistent or longstanding persistent. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center

Amulet – Abbott: Study to determine if Amulet device is safe and effective when compared to Watchman device. Randomized 1:1 Watchman vs Amulet. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center

ASAP Too – Boston Scientific: Evaluate the safety and effectiveness of the Lariat Suture Delivery system to percutaneously isolate and ligate the LAA from the LA as an adjunct to a planned PVI catheter ablation in persistent or longstanding persistent. PI: Dr. Yoaav Krauthammer
Facility: Overland Park Regional Medical Center, Research Medical Center

Diamond AF II – Epix: Evaluate the safety and effectiveness of the Diamond tipped catheter ablation system. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center

Node 301 – Milestone: Determine whether etripamil nasal spray 70 mg self-administered by patients is superior to placebo at terminating episodes of PSVT in an outpatient setting. This is a study that involves the patient coming back for a 2 hour Research visit at OPR. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center

Xe-POHCAS – Neuroprote Xeon Inc.: Evaluation on Days 30 and 90 post OHCA, whether there is a difference in functional outcome in comatose subjects who achieved ROSC within 30 minutes after OHCA and were treated with xenon 50% plus oxygen vs standard of care treatment without xenon during TTM. PI:Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center

GI 268: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locallyadvanced pancreatic adenocarcinoma. PI: Jaswinder Singh, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GU 142: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency. PI: Peter Van Veldhuizen, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GU 155: An Open-Label Phase 1/2A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients with Metastatic Castration-Resistant Prostate Cancer. PI: Dr Peter Van Veldhuizen
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GU 166: A Phase 2, Randomized, Double-Blind, Placebo-ControlledStudy of Abiraterone Acetate plus Prednisone with or withoutAbemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer. PI: Dr Peter Van Veldhuizen
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GYN 80: A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer. PI: Kristopher LyBarger, DO
Facility: Menorah Medical Center, Research Medical Center

GYN 87: Phase 3 trial of maintenance with selinexor/ placebo after combination chemo for advanced or recurrent endometrial cancer. PI: Kristopher LyBarger, DO
Facility: Centerpoint Medical Center, Research Medical Center

LUN 384: A phase III, multicenter, randomized, double blind, placebocontrolled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC). PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LUN 390: Phase II, Study of M7824 versus Pembrolizumab as a First-line in PD-L1 Expressing Advanced NSCLC. PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LUN 396: A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum-Based Chemotherapy with Durvalumab in First-Line Stage IV Non-Small Cell Lung Cancer (ORION). PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LUN 404:

A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600E-mutant Non-small Cell Lung Cancer. PI: Peter VanVeldhuizen, MD


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

PRO 02: My pathway: an open-label phase iia study evaluating trastuzumab/pertuzumab, erlotinib, vemurafenib/ cobimetinib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities predictive of response to one of these agents PI: Jaswinder Singh, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

PRO 10: A Phase II Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in Selected Tumor Types Based on Genomic Alterations. PI: Jaswinder Singh, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center